The fate of pluripotent stem cells is tightly controlled during early embryonic development. Both the derivation and the maintenance of embryonic stem cells (ES cells) in vitro depend on feeder cell-derived growth factors that are largely unidentified. To dissect the mechanisms governing pluripotency, we conducted a screen to identify factors that are produced by mouse embryonic fibroblast STO cells and are required to maintain the pluripotency of ES cells. One of the factors is bone morphogenetic protein 4 (BMP4). Unexpectedly, the major effect of BMP4 on the self-renewal of ES cells is accomplished by means of the inhibition of both extracellular receptor kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways, and inhibitors of ERK and p38 MAPKs mimic the effect of BMP4 on ES cells. Importantly, inhibition of the p38 MAPK pathway by SB203580 overcomes the block in deriving ES cells from blastocysts lacking a functional Alk3, the BMP type IA receptor. These results uncover a paradigm for BMP signaling in the biology of pluripotent stem cells.E mbryonic stem cells (ES cells) are able to form all cell types of the body by following normal embryogenesis (1-3). The pluripotency of ES cells has attracted great attention for their potential use in tissue and cell therapy. However, the molecular and developmental mechanisms controlling pluripotency and differentiation of ES cells are largely unknown, and only a very limited number of genes has so far been shown to affect the fate decisions of inner cell mass (ICM) or ES cells. These genes include Oct4, Fgf4, H2az, Foxd3, Nanog,.Growth factors required for ES cell self-renewal are usually provided by feeder cells, or exogenously (13). Leukemiainhibiting factor (LIF) and its close relatives are the known propluripotency factors for mouse ES cells. It is unclear how many other growth factors or signaling pathways are required for the self-renewal of ES cells. To address these questions, we set out to identify such factors that affect the self-renewal of ES cells. To accomplish this, we isolated and screened sublines of the mouse embryonic fibroblast STO cells for their ability to support the self-renewal of ES cells by using Oct4-GFP as a convenient marker of pluripotency (14-16). By this approach in combination with gene expression profiling, we have identified bone morphogenetic protein 4 (BMP4) as part of the extracellular propluripotency cues. Also, our studies show that BMP4 and LIF have synergistic effect in teratoma formation. Moreover, a number of genes differentially expressed in ES cells cultured with or without exogenous BMP4 have been identified.One of these differentially expressed genes, X-linked inhibitor of apoptosis (Xiap), is expressed at higher levels in ES cells cultured in the presence of exogenous BMP4 than in its absence. XIAP has been implicated in connecting the type I receptors of BMPs and TGF-␤s with the mitogen-activated protein kinase (MAPK) p38 pathway (17)(18)(19)(20). Contrary to previous findings in which BMP signaling up-r...

No abstract

OX40 expressed on activated T cells is known to be an important costimulatory molecule on T cell activation in vitro. However, the in vivo functional significance of the interaction between OX40 and its ligand, OX40L, is still unclear. To investigate the role of OX40L during in vivo immune responses, we generated OX40L-deficient mice and a blocking anti-OX40L monoclonal antibody, MGP34. OX40L expression was demonstrated on splenic B cells after CD40 and anti-immunoglobulin (Ig)M stimulation, while only CD40 ligation was capable of inducing OX40L on dendritic cells. OX40L-deficient and MGP34-treated mice engendered apparent suppression of the recall reaction of T cells primed with both protein antigens and alloantigens and a significant reduction in keyhole limpet hemocyanin–specific IgG production. The impaired T cell priming was also accompanied by a concomitant reduction of both T helper type 1 (Th1) and Th2 cytokines. Furthermore, antigen-presenting cells (APCs) derived from the mutant mice revealed an impaired intrinsic APC function, demonstrating the importance of OX40L in both the priming and effector phases of T cell activation. Collectively, these results provide convincing evidence that OX40L, expressed on APCs, plays a critical role in antigen-specific T cell responses in vivo.

Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation were clarified by means of a case‐control study of matched non‐pregnant and non‐lactating patients with breast cancer. From 18 institutions in Japan, a total of 192 subjects with breast cancer diagnosed during pregnancy (72 cases) and lactation (120 cases) were collected between 1970 and 1988, accounting for 0.76% of all breast cancer patients. The duration of symptoms was longer and tumor size was larger in the study subjects. Although the disease‐free interval was longer than that in the control patients, the survival time was shorter. There was no characteristic difference in histologic type. Vascular invasion and lymph node metastasis were found more frequently in the subjects. The positive rates of estrogen receptor and progesterone receptor were lower in the subjects. The 5‐ and 10‐year survival rates of the study patients were 65% and 55%, respectively, and these survivals were significantly lower than those of the control (P < 0.001). The survival rates were poorer in the subjects, in accordance with stage and lymph node metastasis. The results suggest that most of the patients with breast cancer diagnosed during pregnancy and lactation are in a more advanced stage because of a delay in detection and diagnosis, and hence have unfavorable prognosis. Therefore, it is important to diagnose and treat early for improvement of prognosis in patients with breast cancer during pregnancy and lactation.